Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Oral tofacitinib successfully treated total body hair loss in one patient.

Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.

Getting insurance to cover the hair loss treatment tofacitinib is hard because it's not officially approved for that use.

Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.

Tofacitinib helps regrow hair in severe alopecia patients, but more research is needed.

Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.

Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.

Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.

The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.

High potency topical steroids are the most effective treatment for pediatric alopecia areata.

Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.

Tofacitinib therapy can effectively regrow eyebrows and eyelashes in some alopecia areata patients.

Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.

Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

More extensive trials are needed to understand tofacitinib's role in treating severe hair loss.

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

Tofacitinib helped regrow hair in patients with alopecia, with few side effects.

Tofacitinib is effective and safe for treating severe hair loss in Korean patients.

Traditional treatment for pediatric alopecia areata is most effective and should be first choice.

JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.

New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.

Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.

Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.

Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.

Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.